PD173074

• Catalog No.: S1264
• CAS Number: 219580-11-7
• M. F.: C28H41N7O3
• M. W.: 523.67024
• Storage: -20°C

SYNONYMS

• IUPAC name: 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
• IUPAC Traditional name: 3-tert-butyl-1-(2-{[4-(diethylamino)butyl]amino}-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea

DATABASE IDS

• CAS Number: 219580-11-7

PROPERTIES

• Target: FGFR
• Target: VEGFR
• Salt Data: Free Base
• Storage Condition: -20°C

DETAILS

Description (English)

Research Area

• Description: Cancer

Biological Activity

• Description: PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM.
• Targets: FGFR1
• IC50: ~25 nM ^[1]
• In Vitro: PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGF, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nm.="" inhibition="" of="" afgf-stimulated="" mm="" cell="" growth="" by="" pd173074="" is="" highly="" correlated="" with="" the="" expression="" of="" fgfr3.="" pd173074="" treatment="" completely="" abolishes="" nih="" 3t3="" transformation="" mediated="" by="" y373c="" fgfr3="" but="" not="" by="" ras="" v12,="" demonstrating="" that="" pd173074="" specifically="" targets="" fgfr3-mediated="" cell="" transformation="" and="" lacks="" nonspecific="" cytotoxic="" effect.="" pd173074="" also="" induces="" functional="" maturation="" of="" kms11="" and="" kms18="" cells.="">^[4]
• In Vivo: Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Combination Therapy

• Description: In the H-510 xenograft, the anti-tumor effect of cisplatin is significantly potentiated by coadministration of PD173074. ^[5] The combination of PD173074 with paclitaxel or doxorubicin shows synergistic activity in the FGFR2 mutant cell lines. ^[6]

Protocol

• Protocol: Kinase Assay ^[1]
• In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-^32P]ATP (5 μM ATP containing 0.4 μCi of [γ-^32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [^32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
• Protocol: Cell Assay ^[4]
• Cell Lines: KMS11 and KMS18
• Concentrations: Dissolved in DMSO, final concentrations ~100 nM
• Incubation Time: 48 hours
• Methods: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
• Protocol: Animal Study ^[1]
• Animal Models: Swiss Webster mice with induced corneal angiogenesis
• Formulation: Prepared in sterile fashion
• Doses: ~2 mg/kg/day
• Administration: Administered intraperitoneally

References

• References: [1] Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.
• References: [2] Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.
• References: [3] Bansal R, et al. J Neurosci Res, 2003, 74(4), 486-493.
• References: [4] Trudel S, et al. Blood, 2004, 103(9), 3521-3528.
• References: [5] Pardo OE, et al. Cancer Res, 2009, 69(22), 8645-8651.
• References: [6] Byron SA, et al. Int J Gynecol Cancer, 2012.

REFERENCES

• Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.
• Skaper SD, et al. J Neurochem, 2000, 75(4), 1520-1527.
• Bansal R, et al. J Neurosci Res, 2003, 74(4), 486-493.
• Trudel S, et al. Blood, 2004, 103(9), 3521-3528.
• Pardo OE, et al. Cancer Res, 2009, 69(22), 8645-8651.
• Byron SA, et al. Int J Gynecol Cancer, 2012.